Clinical trials: PD1
Parkinson's Disease (PD), Parkinson's Disease
Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease
This clinical study is being conducted to learn more about a new imaging drug called [18F]MK-0947, which is designed to help doctors see changes in the brain related to Parkinson's disease (PD).
- Conditions
- Parkinson's Disease (PD), Parkinson's Disease, Parkinson's Disease (Disorder)
- Trial name
- NCT07348250
- Testing
- [18F]MK-0947
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Invicro
Esophageal Cancer
Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell
The purpose of this study is to observe and evaluate the efficacy and safety of Anti-PD-1 antibody SHR-1210 plus apatinib versus SHR-1210 as second-line treatment of advanced esophageal squamous cell.
- Trial name
- NCT05049681
- Testing
- Camrelizumab, Apatinib
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Feng Wang
Phaeohyphomycosis
Efficacy of PD-1 Monoclonal Antibody in the Treatment of Phaeohyphomycosis
The main objective was to evaluate the clinical efficacy of PD-1 inhibitor (PD-1 monoclonal antibody) in the treatment of skin and subcutaneous mucocytosis infection, including the comparison of immune cell groups before and…
- Trial name
- NCT06796231
- Where
- China
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Parkinson's Disease
Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain
This is a Phase I clinical trial of the FDA approved drug Glycerol Phenylbutyrate to see if phenylbutyrate can increase the removal of alpha-synuclein from the brain into the bloodstream.
- Trial name
- NCT02046434
- Testing
- Glycerol Phenylbutyrate
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Secondary Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection
Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients
This prospective case-control study aims to evaluate the immune function and find PD-1 antibody efficacy predictors on Chronic Active Epstein-Barr Virus Infection and Epstein-Barr virus-associated hemophagocytic…
- Trial name
- NCT05841342
- Testing
- No intervention
- Where
- China
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Beijing Friendship Hospital
REM Sleep Behavior Disorder, Synucleinopathies
A Comprehensive, Multimodal Characterization of Prodromal PD in Subjects With RBD
Comprehensive characterization of early-stage Parkinson's disease in patients with REM sleep behavior disorder Parkinson's disease (PD) is the fastest-growing neurodegenerative disorder worldwide, significantly affecting quality…
- Conditions
- REM Sleep Behavior Disorder, Synucleinopathies, Parkinson's Disease (PD), Prodromal Parkinson's Disease
- Trial name
- 7T-RBD (NCT07790744)
- Where
- Denmark
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Danish Research Centre for Magnetic Resonance
Chordoma, Chemotherapy Effect
Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma
This phase II trial studies how well Camrelizumab combined with Apatinib work in treating participants with chordoma that has spread to other places in the body, which may interfere with the ability of tumor cells to grow and…
- Trial name
- NCT06140732
- Testing
- camrelizumab and apatinib
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Parkinsons Disease (PD), Healthy Elderly Volunteers
MK-0947 PN-002: An Open-label Study to Evaluate Brain α-synuclein Deposition Using Positron Emission Tomography (PET) and [¹⁸F]MK-0947 in Participants With Parkinson's Disease (PD)
This is a single-center, open-label clinical study designed to evaluate alpha-synuclein (ASYN) deposition in the brain of participants with Parkinson's disease (PD), as compared with healthy elderly (HE) participants.
- Trial name
- NCT07880379
- Testing
- [¹⁸F]MK-0947
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- XingImaging, LLC
Healthy Male Subjects
A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects
The purpose of this study is to evaluate the pharmacokinetic similarity of AK104 with different manufacturing process in healthy male subjects.
- Trial name
- NCT05559554
- Testing
- AK104 (before the change), AK104 (after the change)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Akeso
Parkinson Disease (PD), MSA - Multiple System Atrophy
Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot Phase
This is an open-label, single-center Phase 1 study evaluating the safety, tolerability, and test-retest characteristics of [11C]MODAG-005, an investigational positron emission tomography/computed tomography (PET/CT) radioligand…
- Conditions
- Parkinson Disease (PD), MSA - Multiple System Atrophy, Healthy Adult Participants
- Trial name
- PIOSA (NCT07640542)
- Testing
- [11C]MODAG-005
- Where
- Germany
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Parkinson Disease, Parkinsonian Disorders
Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.
Parkinson's disease (PD) is a degenerative disease that can be difficult to diagnose. The clinicopathological studies had demonstrated a 76% accuracy in the clinical diagnosis of PD.
- Trial name
- NCT01380899
- Testing
- Biopsy of skin
- Where
- Mexico
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de San Luis Potosí
Non-Small Cell Lung Cancer
Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients
Several reports have examined Programmed Death 1 (PD-1) expression on tumor-infiltrating T-cells, and its correlation with prognosis has been discussed.
- Trial name
- NCT02758314
- Testing
- Evaluation of PD-1/PDL-1 expression.
- Where
- Mexico
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
PD1, Acute Myocardial Infarction
Comparison of PD1+T Cell Expression in Peripheral Blood for Cardiac Function Prognosis in Patients With Acute MI
Comparison of high PD1+ T cell and low PD1+ T cell expression in peripheral blood for cardiac function prognosis in Patients with acute myocardial infarction
- Trial name
- NCT05251987
- Testing
- PD1+ T Cell Expression
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Trauma Patients
Effect of Severe Trauma on PD1 and Its Legend (PD1/L1) on T Lymphocytes and Correlation With Mortality
Unlike neuro-endocrine response to trauma; posttraumatic immune alterations are not easily carried out at bedside. The majority of trials were conducted in the intensive care usually hours to days post injury.
- Trial name
- NCT04233723
- Testing
- peripheral blood samples
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
NSCLC
JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC
This is a phase II clinical study to evaluate the safety, tolerability, preliminary efficacy and pharmacokinetics of JS207 (anti-PD-1/VEGF bispecific antibody) combined with platinum-based doublet chemotherapy in subjects with…
- Trial name
- NCT06944470
- Testing
- Paclitaxel + Carboplatin/cisplatin for squamous cell carcinoma and pemetrexed + carboplatin/cisplatin for non-squamous cell carcinoma, surgery, Radiochemotherapy
- Where
- China
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Parkinson Disease
Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study
The PASS-PD study is set out to screen individuals from the general population with an increased risk for the development of Parkinson's Disease (PD) and to investigate this highly enriched cohort longitudinally for five year.
- Trial name
- PASS-PD (NCT04724941)
- Testing
- No intervention
- Where
- Germany
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- University Hospital Schleswig-Holstein
Parkinson Disease
Parkinson's Disease Biomarkers in Nerve Cells in the Gut
Parkinson's disease affects all the nerve cells in the body, including the ones in the gut. The gut contains its own nervous system, the enteric nervous system, and can be thought of as a "second brain".
- Trial name
- PD-ENS (NCT05347407)
- Testing
- Colonoscopy
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Parkinson Disease, Irritable Bowel Syndrome
Early Signs of Parkinsons Disease in IBS
Bowel symptoms like constipation and abdominal pain are characteristic symptoms of irritable bowel syndrome (IBS). The pathogenesis and pathophysiology are not fully understood but subject to intense research, with emphasis on…
- Trial name
- NCT05573542
- Where
- Sweden
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Örebro University, Sweden
Alzheimer Disease, Frontotemporal Dementia
Proteinopathies Expression in Skin of Neurodegenerative Disorders
The goal of this observational study is to compare the aggregation pattern of proteinopathies (alpha-synuclein, amyloid-beta, phosphorylated tau and transactive response DNA -binding protein 43 [TDP43]) in skin biopsies of…
- Conditions
- Alzheimer Disease, Frontotemporal Dementia, Parkinson Disease, Atypical Parkinsonism
- Trial name
- NCT06528964
- Testing
- Immunohistochemistry and immunofluorescence
- Where
- Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de San Luis Potosí
Gastric Cancer
Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer（RC48-C018）
This trial is a multi-center, open, single-arm, superior phase II clinical study.
- Trial name
- NCT05113459
- Testing
- Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Guoxin Li